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Timing of initiation of enzyme replacement therapy after
diagnosis of type 1 Gaucher disease: effect on incidence of
avascular necrosis
Gaucher disease (GD), the most common lysosomal storage
disorder, results from defective activity of acid b-glucosidase
(EC 3.2.1.45; lysosomal glucocerebrosidase) due to mutations
in the GBA gene. Enzyme deﬁciency leads to accumulation of
glucocerebroside in the lysosomes of mononuclear phagocytes
and a complex multisystemic phenotype (Grabowski et al,
2006). The glucocerebroside-engorged macrophages trigger a
chronic inﬂammatory state, immune dysfunction and, occa-
sionally, ﬁbrosis (Cox & Schoﬁeld, 1997). The estimated
prevalence of GD is 1/57 000 (Meikle et al, 1999) to 1/75 000
newborns (Grabowski, 2005) although its prevalence in people
of Ashkenazi Jewish ancestry is higher, at c. 1 in 500 (Weinreb
et al, 2008). Type 1 GD (GD1) comprises c. 94% of all cases,
and it is differentiated from type 2 and type 3 GD by the
absence of primary central nervous system involvement
(Grabowski et al, 2006).
The most prominent sites of pathology in GD1 are the liver,
spleen, bone marrow, skeleton and lungs (Charrow et al, 2000;
Grabowski et al, 2006). Clinical and radiological evidence of
diverse skeletal involvement occurs in the majority of patients
(Charrow et al, 2000; Grabowski et al, 2006; Weinreb et al,
2007). However, skeletal involvement may occur in the absence
of signiﬁcant haematological and visceral abnormalities,
underscoring the extreme heterogeneity of GD1 within the
same genotype groups and even among affected siblings
(Taddei et al, 2009).
Type 1 GD is a progressive condition in which irreversible
disease sequelae can occur in untreated patients (Kaplan et al,
2006; Maaswinkel-Mooij et al, 2000; Taddei et al, 2009). A
major irreversible complication of GD1 is avascular necrosis
(AVN), which can lead to joint destruction, the need for joint
replacement surgery, and chronic disability. AVN may rarely
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Summary
Data from the International Collaborative Gaucher Group Gaucher Registry
were analysed to assess the relationship between enzyme replacement therapy
with imiglucerase (ERT) and incidence of avascular necrosis (AVN) in type 1
Gaucher disease (GD1), and to determine whether the time interval between
diagnosis and initiation of ERT inﬂuences the incidence rate of AVN. All
patients with GD1 enrolled in the Gaucher Registry who received ERT and
did not report AVN prior to starting therapy (n = 2700) were included. The
incidence rate of AVN following initiation of ERT was determined. An
incidence rate of AVN of 13Æ8 per 1000 person-years was observed in patients
receiving ERT. Patients who initiated ERT within 2 years of diagnosis had an
incidence rate of 8Æ1 per 1000 person-years; patients who started ERT
‡2 years after diagnosis had an incidence rate of 16Æ6 per 1000 person-years.
The adjusted incidence rate ratio was 0Æ59 [95% conﬁdence interval (CI)
0Æ36–0Æ96, P =0 Æ0343]. Splenectomy was an independent risk factor for AVN
(adjusted incidence rate ratio 2Æ23, 95% CI 1Æ61–3Æ08, P <0 Æ0001). In
conclusion, the risk of AVN was reduced among patients who initiated ERT
within 2 years of diagnosis, compared to initiating treatment ‡2 years after
diagnosis. A higher risk of AVN was observed among patients who had
previously undergone splenectomy.
Keywords: Gaucher disease, enzyme replacement therapy, avascular necrosis,
imiglucerase.
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and pathological fractures (Elstein et al, 1997). In the natural
course of GD1, the occurrence of AVN appears to be
unpredictable and its risk factors are not understood.
The standard of care for GD1 is enzyme replacement therapy
with imiglucerase (ERT). While enzyme therapy is highly
effective in reversing visceral and haematological manifesta-
tions and some aspects of skeletal disease, its precise impact on
the risk of bone disease, such as AVN, is not known
(Andersson et al, 2005; Barton et al, 1991; Charrow et al,
2007; Cox et al, 2008; Grabowski et al, 2006, 1998; Sims et al,
2008; Weinreb et al, 2007, 2002; Wenstrup et al, 2007). A key
unanswered question regarding the management of GD1
concerns the timing of treatment initiation, and whether early
initiation of ERT after diagnosis reduces the incidence rate of
clinically signiﬁcant events, such as AVN. The present study
used the International Collaborative Gaucher Group (ICGG)
Gaucher Registry database to determine whether the rate of
AVN following treatment initiation varied according to
particular risk factors, including the interval between diagnosis
and initiation of enzyme therapy. Our results provide evidence
on which clinical decisions regarding the optimal timing to
begin ERT can be based.
Methods
ICGG Gaucher Registry
The ICGG Gaucher Registry was launched in 1991 to track the
clinical, demographic, genetic, biochemical and therapeutic
characteristics of patients with GD throughout the world,
irrespective of disease severity and treatment status (Charrow
et al, 2000). The goals of the Registry are to deﬁne the clinical
spectrum of GD, assess its natural history though longitudinal
follow-up and assess the effect of treatment. An independent
international group of physicians who are experts in GD
provide scientiﬁc direction and governance of the Registry,
with logistical support from Genzyme Corporation (Cam-
bridge, MA, USA). Since 1991, with Institutional Review
Board/Ethics Committee approvals, over 700 physicians from
60 countries have voluntarily submitted de-identiﬁed data on
over 5000 patients to the Registry.
Study population
Data included in this study were recorded in the Registry as of
July 2007. ERT refers to mannose-terminated glucocerebrosi-
dase, whether human placenta-derived, alglucerase (Cere-
dase
 ; Genzyme Corporation) or human recombinant
Chinese Hamster Ovary cell-generated, imiglucerase (Cere-
zyme
 ; Genzyme Corporation). Alglucerase and imiglucerase
have been shown to be therapeutically equivalent in a
randomized, two-arm clinical trial (Grabowski et al, 1995).
Of the patients included in this analysis, 44% initiated therapy
with alglucerase and 56% initiated therapy with imiglucerase.
Within several years, most of the patients who initiated
therapy with alglucerase eventually switched to imiglucerase;
only 16% of patients were treated solely with alglucerase
during follow-up.
The dataset for this analysis included all GD1 Registry
patients who received imiglucerase with the following infor-
mation: date of GD diagnosis; age at GD diagnosis; dates of
ﬁrst and last assessments in the Registry; and date of initiation
of therapy. The diagnosis of GD1 was usually based on the
assay of acid b-glucosidase activity and/or genotyping of GBA.
The objective of the analysis was to estimate the incidence
rate of new onset AVN following treatment initiation.
Therefore, patients with AVN reported before initiation of
therapy were excluded from this analysis.
Demographic and clinical characteristics of patients
Patient demographics and clinical manifestations of GD1 were
characterized at the time of therapy initiation. Clinical
manifestations included whether prior therapeutic splenec-
tomy had been performed, haemoglobin concentration, plate-
let count, spleen volume, liver volume, bone mineral density
and reports of bone pain and/or bone crisis. Criteria for
diagnosis of bone crises in the Registry include acute onset of
bone pain requiring immobilisation of the affected area and
narcotics for the relief of pain, accompanied by one or more of
the following: periosteal elevation, elevated white blood cell
count, elevated inﬂammatory markers, fever or debilitation
>3 d (Charrow et al, 2007). This deﬁnition excluded fracture
and osteomyelitis. Bone pain was deﬁned as patient-reported
pain experienced during the 30-d period preceding the report
and attributable to Gaucher disease according to the clinical
judgment of the reporting physician.
Ascertainment of avascular necrosis
Avascular necrosis was typically ascertained from X-ray or
magnetic resonance imaging (MRI) results. The recommended
radiological guidelines for patients with GD1 include assess-
ment of the hip, femur, pelvis and lumbar spine. The date of
onset and site of AVN was recorded on the skeletal assessment
case report forms of the Registry. If a patient had AVN
reported on more than one date, the patient’s earliest date of
AVN onset was identiﬁed.
Person-time of follow-up
Follow-up began on each patient’s date of initiation of therapy
in the Registry. Patients were followed until either the date of
AVN onset, or for patients who did not develop AVN, the date
of their last recorded assessment in the Registry. Each patient
was classiﬁed according to the duration of time between
diagnosis of GD1 and initiation of therapy. The categories were
as follows: <1; 1–<2; 2–<5; 5–<10; 10–<20; 20–<30; and
30+ years.
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Descriptive statistics were used to analyse data in this study
according to demographics and clinical characteristics of GD1.
Proportions were calculated for categorical variables (i.e.
gender, genotype, ethnicity). Summary statistics (mean, stan-
dard deviation, percentiles) were calculated for continuous
measures (i.e. age). Incidence rates were calculated as follows:
P
AVN Cases
PPerson yearsof follow up
ðamongallpatientsinthestudyÞ
  1000
Other candidate risk factors for new onset AVN were
collectively examined through construction of a multivariate
Poisson regression model. Variables in the model included
interval between GD diagnosis and initiation of therapy (<2,
2 years or more), age at initiation of therapy, age at Gaucher
diagnosis, gender, year of diagnosis (before 1991, 1991–1999,
2000 or later), splenectomy before initiation of therapy,
calendar year of initiation of therapy (before 1995, 1995–
1999, 2000 or later), and genotype category (N370S/N370S,
N370S/Other, Other/Other). Results from the multivariate
Poisson regression model were expressed as adjusted incidence
rate ratios. The risk of AVN over time following initiation of
therapy was depicted by construction of a Kaplan–Meier curve.
An alpha-level of 0Æ05 was used to determine statistical
signiﬁcance.
All analyses were conducted in SAS 8.2 (SAS Institute Inc.,
Cary, NC, USA) in accordance with STROBE guidelines
(http://www.strobe-statement.org, accessed 15 June 2009).
Results
As of July 2007 of a total of 4783 patients were enrolled in the
ICGG Gaucher Registry; 3176 patients met the study inclusion
criteria, i.e., received ERT, reported dates of therapy initiation
and GD1 diagnosis, and reported age at diagnosis. The ﬁnal
analysis was based on 2700 patients; 476 of 3176 patients were
excluded because they had a history of AVN before therapy
initiation.
The incidence rate of new onset AVN among GD1 patients
following initiation of therapy was 13Æ8 per 1000 person-years
(Table I). Incidence rates then were stratiﬁed by interval in
years between diagnosis and initiation of ERT. Among patients
who initiated therapy within 2 years after diagnosis, the
incidence rate of AVN following initiation of imiglucerase
ranged from 8Æ0t o8 Æ2 per 1000 person-years. In contrast, the
incidence rate of AVN among patients starting therapy more
than 2 years after diagnosis (up to 30 years) rose progressively
from 12Æ7t o2 2 Æ1 per 1000 person-years. Therefore, we
consolidated our analysis of the rate of AVN on ERT into
two groups: patients who started ERT within 2 years of
diagnosis and those who started ERT 2 years or more after
diagnosis.
Ascertainment of AVN was by MRI in 54% of cases and
plain radiology for 41% of cases. The sites of AVN were the hip
(52%), femur (21%), shoulder (6%), humerus (3%), tibia
(2%), knee (2%), spine (<1%), ankle (<1%), wrist (<1%) and
jaw (<1%); in 11% of cases, AVN occurred at multiple sites.
The characteristics of patients included in this analysis are
depicted in Table II, stratiﬁed according to whether therapy
was initiated within 2 years or 2 or more years after diagnosis.
Additional patient characteristics are provided in Table SI.
There were similar proportions of men (47%) and women
(53%). The majority of patients were from the US (40%),
Americas including Canada (21%) and Europe (25%). The
most common race/ethnicities were non-Jewish Caucasians
(41%) and Jewish (35%). Genotypes were reported for c. 70%
of the patients; the majority (87%) had at least one N370S
allele (26% homozygous, 61% heteroallelic).
In the group of patients who initiated therapy within 2 years
following diagnosis, there were substantially more patients
below age 10 years at therapy initiation (42%) and non-Jewish
patients (76%) compared to the group of patients who
initiated therapy 2 years or more following diagnosis (10%
and 58%, respectively). However, the distributions of age at
Gaucher diagnosis and genotypes were similar between the
groups. As expected, 98% of patients who initiated therapy
within 2 years following diagnosis were diagnosed after 1991
(when alglucerase ﬁrst became available, i.e., during the ERT
era), while the majority (71%) of patients in the group of
patients who initiated therapy 2 years or more following
diagnosis were diagnosed before 1991, i.e., during the pre-ERT
era.
The haematological, visceral organ and skeletal character-
istics at time of therapy initiation are shown in Table III.
Overall, among patients with assessments reported, 43% had
anaemia; 62% had platelet counts <120 · 10
9/l; 89% had
spleen volumes >5 multiples of normal, and 71% had liver
volumes >1Æ25 multiples of normal. Bone pain around the
time of ﬁrst infusion was reported in 46% of all patients
and low bone mineral density in 26%. There were no
substantial differences between the <2 and ‡2 years groups
Table I. Incidence rates of avascular necrosis according to time
interval between Gaucher disease diagnosis and initiation of therapy.
AVN
cases
Number of
patients
Person-years
of follow-up
Incidence
rate*
Total 213 2700 15 468 13Æ8
Years between Gaucher disease diagnosis and initiation of ERT with
imiglucerase
<1 24 639 3018 8Æ0
1–<2 17 408 2066 8Æ2
2–<5 30 394 2369 12Æ7
5–<10 35 375 2468 14Æ2
10–<20 48 440 2844 16Æ9
20–<30 33 244 1493 22Æ1
30+ 26 200 1210 21Æ5
*Incidence rate per 1000 person-years.
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bone pain or bone mineral density. However, patients who
initiated therapy 2 years or more following diagnosis were
more likely to have reported a bone crisis around the time
of initiation of treatment (16%, n = 123 of 772) compared
to those in the <2 years group (6%, n = 35 of 607).
Furthermore, there was a striking difference in prevalence of
splenectomy in the two treatment groups: 32% (n = 522 of
1653) of the patients in the ‡2 years group had undergone
splenectomy compared to only 6% (n = 65 of 1047) of the
patients in whom treatment was initiated <2 years from date
of diagnosis.
The adjusted incidence rate ratio of AVN according to the
time interval between GD diagnosis and initiation of therapy,
which was analysed using a multivariate Poisson regression
model, is shown in Table IV. Patients in whom ERT was
initiated within 2 years of diagnosis of GD1 had approxi-
mately half the incidence rate of AVN (8Æ1 per 1000 person-
years) compared to patients who started therapy 2 or more
years after diagnosis (16Æ6 per 1000 person-years). The
incidence rate difference between the two groups was 8Æ5
per 1000 person years [95% conﬁdence interval (CI) 5Æ0–12Æ0
per 1000 person-years]. The multivariate Poisson regression
analysis indicates that the adjusted incidence rate ratio of 0Æ59
(95% CI 0Æ36–0Æ96, P =0 Æ0343) represents a 41% decrease in
the risk of AVN in patients who began ERT within 2 years
following diagnosis. Splenectomy was an independent risk
factor for AVN after adjusting for all other variables in the
model. The adjusted incidence rate ratio for AVN among
patients who were asplenic at the time of initiation of therapy
was 2Æ23 (95% CI 1Æ61–3Æ08, P <0 Æ0001) compared to those
who had an intact spleen. Women had a lower risk of AVN
Table II. Characteristics of patients.
Years between Gaucher
diagnosis and initiation of
ERT with imiglucerase
Total
(N = 2700)
<2 years
(N = 1047)
‡2 years
(N = 1653)
Gender, n (%) n = 1047 n = 1653 n = 2700
Male 539 (51Æ5) 719 (43Æ5) 1258 (46Æ6)
Female 508 (48Æ5) 934 (56Æ5) 1442 (53Æ4)
Age at Gaucher diagnosis (years), n (%) n = 1047 n = 1653 n = 2700
0–9 471 (45Æ0) 713 (43Æ1) 1184 (43Æ9)
10–19 171 (16Æ3) 317 (19Æ2) 488 (18Æ1)
20–29 120 (11Æ5) 278 (16Æ8) 398 (14Æ7)
30–39 111 (10Æ6) 151 (9Æ1) 262 (9Æ7)
40–49 84 (8Æ0) 107 (6Æ5) 191 (7Æ1)
50–59 46 (4Æ4) 47 (2Æ8) 93 (3Æ4)
‡60 44 (4Æ2) 40 (2Æ4) 84 (3Æ1)
Age at initiation of ERT with
imiglucerase (years), n (%)
n = 1047 n = 1653 n = 2700
0–9 444 (42Æ4) 164 (9Æ9) 608 (22Æ5)
10–19 174 (16Æ6) 326 (19Æ7) 500 (18Æ5)
20–29 116 (11Æ1) 276 (16Æ7) 392 (14Æ5)
30–39 117 (11Æ2) 307 (18Æ6) 424 (15Æ7)
40–49 95 (9Æ1) 265 (16Æ0) 360 (13Æ3)
50–59 54 (5Æ2) 161 (9Æ7) 215 (8Æ0)
‡60 47 (4Æ5) 154 (9Æ3) 201 (7Æ4)
Year of Gaucher diagnosis, n (%) n = 1047 n = 1653 n = 2700
Before 1991 21 (2Æ0) 1175 (71Æ1) 1196 (44Æ3)
1991–1999 504 (48Æ1) 387 (23Æ4) 891 (33Æ0)
2000 or later 522 (49Æ9) 91 (5Æ5) 613 (22Æ7)
Year of initiation of ERT with
imiglucerase, n (%)
n = 1047 n = 1653 n = 2700
Before 1995 170 (16Æ2) 682 (41Æ3) 852 (31Æ6)
1995–1999 329 (31Æ4) 532 (32Æ2) 861 (31Æ9)
2000 or later 548 (52Æ3) 439 (26Æ6) 987 (36Æ6)
Genotype, n (%) n = 704 n = 1166 n = 1870
N370S/N370S 169 (24Æ0) 317 (27Æ2) 486 (26Æ0)
N370S/Other 396 (56Æ3) 739 (63Æ4) 1135 (60Æ7)
Other/Other 139 (19Æ7) 110 (9Æ4) 249 (13Æ3)
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0Æ99, P =0 Æ0412). There were no other clear trends in the risk
of AVN according to age at therapy initiation, age at Gaucher
diagnosis, year of diagnosis, year of therapy initiation and
genotype.
The Kaplan–Meier analysis revealed a reduction in risk of
AVN after 5 years of ERT among patients who began
treatment within 2 years of diagnosis and this decrease in
risk became more striking with subsequent follow up
(Fig 1).
Table III. Clinical characteristics of patients.
Years between Gaucher
diagnosis and initiation of
ERT with imiglucerase
Total patients
(N = 2700)
<2 years
(N = 1047)
‡2 years
(N = 1653)
Anaemia at ﬁrst infusion* , n (%) N = 598 n = 967 n = 1565
Yes 269 (45Æ0) 397 (41Æ1) 666 (42Æ6)
No 329 (55Æ0) 570 (58Æ9) 899 (57Æ4)
Platelet count (·10
9/l) at ﬁrst
infusion*, n (%)
N = 600 n = 963 n = 1563
‡120 219 (36Æ5) 372 (38Æ6) 591 (37Æ8)
60–<120 290 (48Æ3) 378 (39Æ3) 668 (42Æ7)
<60 91 (15Æ2) 213 (22Æ1) 304 (19Æ4)
Spleen volume (multiples of normal)
at ﬁrst infusion , n (%)
n = 334 n = 435 n = 769
£5 35 (10Æ5) 53 (12Æ2) 88 (11Æ4)
>5–£15 161 (48Æ2) 185 (42Æ5) 346 (45Æ0)
>15 138 (41Æ3) 197 (45Æ3) 335 (43Æ6)
Liver volume (multiples of normal)
at ﬁrst infusion , n (%)
n = 317 n = 543 n = 860
£1Æ25 90 (28Æ4) 163 (30Æ0) 253 (29Æ4)
>1Æ25–£2Æ5 188 (59Æ3) 295 (54Æ3) 483 (56Æ2)
>2Æ5 39 (12Æ3) 85 (15Æ7) 124 (14Æ4)
Low bone mineral density at
ﬁrst infusion§–, n (%)
n = 104 n = 137 n = 241
Yes 33 (31Æ7) 30 (21Æ9) 63 (26Æ1)
No 71 (68Æ3) 107 (78Æ1) 178 (73Æ9)
Bone pain at ﬁrst infusion§, n (%) n = 214 n = 487 n = 701
Yes 106 (49Æ5) 214 (43Æ9) 320 (45Æ6)
No 108 (50Æ5) 273 (56Æ1) 381 (54Æ4)
Bone crisis at ﬁrst infusion§, n (%) n = 607 n = 772 n = 1379
Yes 35 (5Æ8) 123 (15Æ9) 158 (11Æ5)
No 572 (94Æ2) 649 (84Æ1) 1221 (88Æ5)
Partial or total splenectomy prior to
initiation of ERT with imiglucerase, n (%)
n = 1047 n = 1653 n = 2700
Yes 65 (6Æ2) 522 (31Æ6) 587 (21Æ7)
No 979 (93Æ5) 1127 (68Æ2) 2106 (78Æ0)
Unknown 3 (0Æ3) 4 (0Æ2) 7 (0Æ3)
*Represents the data point closest to the ﬁrst infusion date, no more than 8 weeks before through
to 2 weeks following the date of ﬁrst infusion.
 Anaemia was deﬁned according to age and gender norms for haemoglobin concentrations as
follows: <120 g/l for males older than 12 years; <110 g/l for females older than 12 years; <105 g/l
for children aged >2–12 years; <95 g/l for children aged 6 months–2 years; <101 g/l for children
younger than 6 months of age.
 Represents the data point closest to the ﬁrst infusion date, no more than 6 months before
through to 6 weeks following the date of ﬁrst infusion.
§Represents the data point closest to the ﬁrst infusion date, no more than 2 years before through
to 6 weeks following the date of ﬁrst infusion.
–Among patients less than age 50 years, lumbar spine z-score of )2 or lower; Among patients aged
50 years or older, lumbar spine t-score of )2Æ5 or lower.
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Avascular necrosis is a severe and irreversible complication of
GD1 that frequently leads to functional disability (Wolfe &
Taylor-Butler, 2000). Even after acute debilitating symptoms
subside, patients suffer from chronic joint destruction, pain
and progressive immobility. Joint replacement is frequently
necessary, but, despite modern techniques, surgery is not
always effective in restoring freedom from dependency on
orthopaedic assistive devices or wheelchair conﬁnement (Sims
et al, 2008; Weinreb et al, 2007). Reports of patients on
imiglucerase treatment, which is highly effective in reversing
the haematological and splenic/hepatic manifestations of GD1,
indicate decreased bone pain (El-Beshlawy et al, 2006) and
Table IV. Multivariate analysis: incidence rates and adjusted incidence rate ratios of AVN.
AVN
cases
Number of
patients
Person-years
of follow-up
Incidence
rate*
Adjusted
incidence rate
ratio 
95% conﬁdence
interval
P-value Lower Upper
Total 213 2700 15 468 13Æ8
Years between diagnosis and initiation of ERT with Imiglucerase
<2 41 1047 5084 8Æ10 Æ59 0Æ36 0Æ96 0Æ0343
‡2 172 1653 10 384 16Æ6 Ref
Gender
Female 110 1442 8499 12Æ90 Æ75 0Æ57 0Æ99 0Æ0412
Male 103 1258 6969 14Æ8 Ref
Age at Gaucher diagnosis
0–9 97 1184 7421 13Æ11 Æ23 0Æ66 2Æ30 Æ5193
10–19 41 488 2563 16Æ01 Æ30 0Æ71 2Æ36 0Æ3910
20–29 36 398 2223 16Æ21 Æ19 0Æ65 2Æ19 0Æ5649
30–39 17 262 1415 12Æ0 Ref
40–49 11 191 998 11Æ00 Æ96 0Æ44 2Æ09 0Æ9100
50–59 7 93 491 14Æ31 Æ03 0Æ40 2Æ65 0Æ9448
‡60 4 84 357 11Æ20 Æ93 0Æ27 3Æ28 0Æ9156
Age at initiation of ERT with imiglucerase
0–9 28 608 3547 7Æ90 Æ67 0Æ35 1Æ28 0Æ2226
10–19 36 500 3025 11Æ90 Æ84 0Æ50 1Æ41 0Æ5102
20–29 46 392 2228 20Æ61 Æ42 0Æ90 2Æ25 0Æ1345
30–39 34 424 2342 14Æ5 Ref
40–49 28 360 2123 13Æ20 Æ93 0Æ55 1Æ58 0Æ8005
50–59 26 215 1218 21Æ31 Æ63 0Æ93 2Æ88 0Æ0904
‡60 15 201 985 15Æ21 Æ21 0Æ58 2Æ53 0Æ6049
Year of Gaucher diagnosis
Before 1991 141 1196 8295 17Æ00 Æ63 0Æ27 1Æ48 0Æ2880
1991–1999 56 891 5614 10Æ00 Æ87 0Æ42 1Æ79 0Æ7072
2000 or Later 16 613 1559 10Æ3 Ref
Year of initiation of ERT with imiglucerase
Before 1995 117 852 6708 17Æ41 Æ23 0Æ74 2Æ04 0Æ4242
1995–1999 60 861 5905 10Æ20 Æ76 0Æ46 1Æ28 0Æ3059
2000 or Later 36 987 2855 12Æ6 Ref
Splenectomy before initiation of ERT with imiglucerase 
Yes 94 587 3500 26Æ92 Æ23 1Æ61 3Æ08 <0Æ0001
No 117 2106 11 943 9Æ8 Ref
Genotype
N370S/N370S 36 486 3109 11Æ6 Ref
N370S/Other 103 1135 7415 13Æ91 Æ11 0Æ74 1Æ67 0Æ6005
Other/Other 23 249 1612 14Æ31 Æ21 0Æ68 2Æ13 0Æ5181
Not reported 51 830 3332 15Æ31 Æ15 0Æ73 1Æ80 0Æ5402
*Incidence rate per 1000 person-years.
 Incidence rate ratios adjusted for all variables shown in the table through a multivariate Poisson regression model. Model excludes seven patients
who received a splenectomy with an unknown date of procedure.
 Excludes seven patients who received a splenectomy but the date of the procedure was unknown.
Ref = reference category used to calculate adjusted incidence rate ratio for each variable.
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sition, bone mass (El-Beshlawy et al, 2006; Rosenthal et al,
1995), bone mineral density (Bembi et al, 2002; Wenstrup
et al, 2007), growth rates in children (Bembi et al, 2002;
El-Beshlawy et al, 2006) and decreased numbers of other
skeletal complications (Sims et al, 2008).
Using data from the ICGG Gaucher Registry, this study
reports the incidence rates of AVN in a large, international,
diverse GD1 patient population after initiation of ERT. The
overall risk of AVN following treatment initiation was 13Æ8 per
1000 person years of follow-up. The risk of AVN on ERT was
lower among patients who began treatment within 2 years of
diagnosis compared to those who started treatment after
2 years or more. The risk following treatment initiation was
not associated with any GBA genotype category but was highly
associated with splenectomy status.
The natural history and clinical manifestations of GD1 are
markedly heterogeneous. In particular, the occurrence of AVN
is unpredictable and its predisposing risk factors and mech-
anistic basis are not yet understood. There is no apparent
correlation of risk of AVN with the severity of splenic, hepatic
or haematological disease. However, we observed that patients
who started treatment 2 years or more after GD diagnosis
reported more bone crises around the time of treatment
initiation (Table III). It is possible that bone crises may be an
intermediate step in disease progression and indicator of
future development of AVN. In addition, one report (Wolfe &
Taylor-Butler, 2000) linked AVN and bone disease in GD1
with blood cell damage, which may be associated with
activation of the coagulation cascade including the abnormal
presence of thrombin-anti-thrombin complexes or increases in
D-dimer (a particular ﬁbrin degradation product) concentra-
tions (Hollak et al, 1997). Abnormalities in red cell deform-
ability may also be associated with GD (Bax et al, 2005) and
AVN (Wolfe & Taylor-Butler, 2000). Persistent increases in
plasma macrophage inﬂammatory proteins MIP-a and MIP-b
as well as other biomarkers of chronic inﬂammation have also
been reported in patients both with and without GD1-
associated AVN (van Breemen et al, 2007). Perturbations in
immunoregulatory anti-inﬂammatory cytokines such as inter-
leukin-10 have also been reported in association with AVN
(Mori et al, 2001) as well as in experimental GD models and
GD1 patients (de Fost et al, 2008; Kacher & Futerman, 2009).
It is unclear as to how these abnormalities relate to the
primary pathophysiology of GD1 or whether they directly
contribute to the development of AVN. Patients who were
diagnosed with GD1 before ERT was available often suffered
from progressive disease complications. Currently, however,
once diagnosed, symptomatic patients may be promptly
treated. The incremental risk for AVN with increasing interval
from diagnosis to initiation of ERT suggests that the proba-
bility of developing post-treatment AVN is substantially
impacted by the total duration of the pre-treatment phase.
Studies using animal models (Enquist et al, 2006) may provide
insight into whether prolonged untreated GD1 leads to
refractory changes in bone microvasculature due to chronic
inﬂammation that may limit the effectiveness of ERT for
prevention of AVN.
For patients without reported osteonecrosis who begin
treatment 2 or more years after diagnosis of GD1, the Kaplan–
Meier analysis suggests there is a 20% probability of develop-
ing AVN within 15–16 years (Fig 1). In children and young
adults, this represents a signiﬁcant lifetime risk. However, the
multivariate Poisson regression model shows that, aside from
timing of therapy initiation, prior splenectomy is also an
independent risk factor for the development of AVN while on
imiglucerase therapy. Because nearly one third of the patients
who began treatment 2 or more years after diagnosis of GD1
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Fig 1. Kaplan–Meier curve.
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formed much more rarely at present, our projection of lifetime
risk of post-ERT AVN may be overstated for newly diagnosed
patients.
The role of splenectomy in increasing the risk of AVN has
been controversial with reports both in favour (Fleshner et al,
1991)aswellasagainstsuchanassociation(Lee,1982).Here,we
found the risk of AVN in splenectomized patients after starting
ERT is more than twofold higher than that of non-splenectom-
ized patients; furthermore this increased risk persisted with
enzyme therapy. Prior to the availability of ERT, splenectomy
was commonly performed to control signs and symptoms of
GD1 including severe cytopenias and abdominal discomfort
(Cox et al, 2008). Splenectomy should only be considered in
exceptional circumstances after assessment by a physician
experienced in the management of GD (Cox et al, 2008).
This analysis has a number of limitations related to the
Gaucher Registry design and study exclusion criteria. All
Registry data are retrospective and unaudited. We have not
attemptedtoascertaintheincidenceofAVNinasymptomaticor
mildly affected GD1 patients who are not considered to be
candidatesforERT.BecausecriteriaforinitiationofERTarenot
dictatedbytheRegistryandvaryconsiderablyamongphysicians
and geographic locales, the population of treated patients that
analysed in this study was clinically heterogeneous. The treat-
ment groups were comparable in terms of ERT dosing. How-
ever, we did not attempt to determine whether imiglucerase
dose or schedule affects the overall incidence of AVN.
Furthermore, because this was not a randomized trial, there
is always the concern of residual confounding, particularly
according to variables not captured in the Registry. We were
unable to assess the inﬂuence of known non-GD1 related risk
factors for AVN, such as corticosteroids, alcohol, trauma and
cancer (Wolfe & Taylor-Butler, 2000). However, we believe
residual confounding according to these variables is unlikely,
as bias would have been introduced into our study only if the
distributions of such risk factors varied according to the time
interval between Gaucher diagnosis and initiation of therapy.
A common concern in any observational study that relies on
diagnostic screening for outcome ascertainment is the possi-
bility of lead-time bias (Rothman, 2002). If this bias were
present in our study, the differences in the incidence of AVN
may be explained by systematically different levels of AVN
screening in the study groups. It may be hypothesized that
patients who initiated therapy sooner following Gaucher
diagnosis may have received more screening and follow-up
than others. This increased screening and follow-up would be
expected to detect onset of AVN earlier and more frequently.
However, our data indicate lower rates of AVN in patients who
initiated therapy within 2 years following diagnosis, suggesting
that lead-time bias could not have played a role in our study.
In this study we did not assess the incidence rates of AVN in
untreated patients as such an analysis could invite assumptions
about the effect of ERT on rates of AVN in Gaucher disease.
The analytical methods used in this paper are not designed to
assess the therapeutic effect of any particular treatment. A
separate study of the factors that inﬂuence the rates of AVN in
untreated Gaucher disease is in progress.
TheRegistrydoesnothavestandardizeddiagnosticcriteriafor
reportingAVN.AVNmay,attimes,beasymptomaticandevolve
slowly over years rendering the diagnosis difﬁcult. The Registry
hasformulated arecommended scheduleofskeletalassessments
but compliance is voluntary. The requested anatomical sites for
serial imaging are restricted to the hips, femora, pelvis, and,
more recently, the lumbosacral spine. Asymptomatic AVN sites
in other skeletal areas may therefore be missed, causing
underestimation of the incidence in all groups that we studied.
Moreover,wedonotyetknowtheextenttowhicharadiological
ﬁnding of AVN in an asymptomatic patient correlates with
eventual functional disability and decreased health-related
quality of life. Therefore, some caution should be exercised in
concluding that the decreased incidence of de novo post-
treatment AVN that we observed in GD1 patients in whom
imiglucerase infusions were initiated within 2 years of diagnosis
translates into an unequivocal clinical beneﬁt. However, our
ﬁndings clearly demonstrate that in some patients, later
initiation of therapy following diagnosis can potentially result
in skeletal pathology that may cause irreversible morbidity and
disability. Pending a better understanding of the biological
mechanisms that contribute to the development of AVN in
patients with GD1 our ﬁndings support earlier rather than later
therapeutic intervention in symptomatic patients.
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